Retina

Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.

Rishi Singh, MD, provides an overview of the various treatment options available for diabetic retinopathy and diabetic macular edema (DR/DME).

The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.

Three of Frontera’s gene therapy product candidates have entered clinical trials since the beginning of the year.

According to a news release, Akari is targeting an Investigational New Drug application submission to the FDA in the first half of 2024.

The collaboration may provide insights to help improve the treatment paradigm for retinal disorders.

The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.

Sharing data between ophthalmologists, optometrists can lead to earlier diagnosis

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

Rishi Singh, MD, provides an overview of the stages of diabetic retinopathy and diabetic macular edema (DR/DME) and the retinal findings associated with each stage as well as factors to consider when selecting therapy.

Carolyn Majcher, OD, FAAO, discusses when to refer patients with diabetic retinopathy and diabetic macular edema (DR/DME) to a retina specialist.

Roche announced that faricimab met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept.

The approval of aflibercept for preterm infants with retinopathy of prematurity (ROP) expands the treatment armamentarium for these patients, comments Prof Anat Loewenstein.

According to Regeneron, aflibercept injection is now approved to treat five retinal conditions caused by ocular angiogenesis.

According to the company, EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.

According to investigators, a new proposed classification for large and extra-large full-thickness macular holes is based on the surgical results achieved with different surgical techniques

Physician discusses existing advancements, innovations for treatment.

Carolyn Majcher, OD, FAAO, describes challenges primary eye care providers can experience when diagnosing diabetic retinopathy and diabetic macular edema (DR/DME).

Diabetic retinal disease experts discuss the standard diagnostic imaging tools that are available to detect diabetic retinopathy and diabetic macular edema (DR/DME).

Specialists seek more information for use in the treatment of patients diagnosed with retinal diseases

HG004 aims to be more effective than other AAV2 products in treatment of inherited retinal diseases caused by mutations in the RPE65 gene.

The workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Carolyn Majcher, OD, FAAO, provides an overview of the symptoms of diabetic retinopathy and diabetic macular edema (DR/DME) and recommendations for dilated eye exams for patients with type 1 and type 2 diabetes.

Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss the current prevalence and future projections of diabetic retinopathy and diabetic macular edema (DR/DME) as well as the impact of early diagnosis and treatment for patients with diabetic retinal diseases.

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

According to the company, it is planning to hold an end-of-phase 2 meeting with the FDA to discuss the results.